Comment: Dengue vaccine development. Thai schoolchildren randomised, controlled phase 2b trial

The Lancet  
Nov 03, 2012  Volume 380  Number 9853  p1531 – 1620  e8 – 9
http://www.thelancet.com/journals/lancet/issue/current

Comment
Dengue vaccine development: a 75% solution?
Scott B Halstead

Preview
A completed clinical trial of vaccine efficacy should be cause for celebration for the billions of people who live in the 128 countries where dengue viruses (DENV) are transmitted.1,2 However, the celebration will be muted this time, as was the case after announcement of results of early clinical trials of vaccines for malaria and HIV.3,4 The low efficacies reported from trials of malaria and HIV vaccines were not entirely unexpected, since these pathogens are known for antigenic complexity and for their ability to successfully evade immune elimination.

Articles
Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial
Arunee Sabchareon, Derek Wallace, Chukiat Sirivichayakul, Kriengsak Limkittikul, Pornthep Chanthavanich, Saravudh Suvannadabba, Vithaya Jiwariyavej, Wut Dulyachai, Krisana Pengsaa, T Anh Wartel, Annick Moureau, Melanie Saville, Alain Bouckenooghe, Simonetta Viviani, Nadia G Tornieporth, Jean Lang

Summary
Background
Roughly half the world’s population live in dengue-endemic countries, but no vaccine is licensed. We investigated the efficacy of a recombinant, live, attenuated tetravalent dengue vaccine.

Methods
In this observer-masked, randomised, controlled, monocentre, phase 2b, proof-of-concept trial, healthy Thai schoolchildren aged 4—11 years were randomly assigned (2:1) to receive three injections of dengue vaccine or control (rabies vaccine or placebo) at months 0, 6, and 12. Randomisation was by computer-generated permuted blocks of six and participants were assigned with an interactive response system. Participants were actively followed up until month 25. All acute febrile illnesses were investigated. Dengue viraemia was confirmed by serotype-specific RT-PCR and non-structural protein 1 ELISA. The primary objective was to assess protective efficacy against virologically confirmed, symptomatic dengue, irrespective of severity or serotype, occurring 1 month or longer after the third injection (per-protocol analysis). This trial is registered at ClinicalTrials.gov, NCT00842530.

Findings
4002 participants were assigned to vaccine (n=2669) or control (n=1333). 3673 were included in the primary analysis (2452 vaccine, 1221 control). 134 cases of virologically confirmed dengue occurred during the study. Efficacy was 30·2% (95% CI −13·4 to 56·6), and differed by serotype. Dengue vaccine was well tolerated, with no safety signals after 2 years of follow-up after the first dose.

Interpretation
These data show for the first time that a safe vaccine against dengue is possible. Ongoing large-scale phase 3 studies in various epidemiological settings will provide pivotal data for the CYD dengue vaccine candidate.

Funding
Sanofi Pasteur.

Hepatitis E vaccine debuts

Nature  
Volume 491 Number 7422 pp7-154  1 November 2012
http://www.nature.com/nature/current_issue.html

News in Focus
Hepatitis E vaccine debuts
Success of Chinese biotech partnership raises hopes for prevention of overlooked diseases.
Soo Bin Park

Batches of the world’s first vaccine against the hepatitis E virus began rolling out of a Chinese factory last week, promising to stem a disease that every year infects about 20 million people and claims 70,000 lives. The vaccine is being hailed as a victory for an unusual public–private partnership that could set a precedent in China’s burgeoning biotechnology sector, and help to deliver other vaccines for diseases overlooked in the West…

http://www.nature.com/news/hepatitis-e-vaccine-debuts-1.11687

Mumps Outbreak in Orthodox Jewish Communities in the United States

New England Journal of Medicine
November 1, 2012  Vol. 367 No. 18
http://content.nejm.org/current.shtml

Original Aticles
Mumps Outbreak in Orthodox Jewish Communities in the United States
A.E. Barskey and Others

Background
By 2005, vaccination had reduced the annual incidence of mumps in the United States by more than 99%, with few outbreaks reported. However, in 2006, a large outbreak occurred among highly vaccinated populations in the United States, and similar outbreaks have been reported worldwide. The outbreak described in this report occurred among U.S. Orthodox Jewish communities during 2009 and 2010.

Methods
Cases of salivary-gland swelling and other symptoms clinically compatible with mumps were investigated, and demographic, clinical, laboratory, and vaccination data were evaluated.

Results
From June 28, 2009, through June 27, 2010, a total of 3502 outbreak-related cases of mumps were reported in New York City, two upstate New York counties, and one New Jersey county. Of the 1648 cases for which clinical specimens were available, 50% were laboratory-confirmed. Orthodox Jewish persons accounted for 97% of case patients. Adolescents 13 to 17 years of age (27% of all patients) and males (78% of patients in that age group) were disproportionately affected. Among case patients 13 to 17 years of age with documented vaccination status, 89% had previously received two doses of a mumps-containing vaccine, and 8% had received one dose. Transmission was focused within Jewish schools for boys, where students spend many hours daily in intense, face-to-face interaction. Orchitis was the most common complication (120 cases, 7% of male patients ≥12 years of age), with rates significantly higher among unvaccinated persons than among persons who had received two doses of vaccine.

Conclusions
The epidemiologic features of this outbreak suggest that intense exposures, particularly among boys in schools, facilitated transmission and overcame vaccine-induced protection in these patients. High rates of two-dose coverage reduced the severity of the disease and the transmission to persons in settings of less intense exposure.

Sexual Activity–Related Outcomes After Human Papillomavirus Vaccination of 11- to 12-Year-Olds

Pediatrics
November 2012, VOLUME 130 / ISSUE 5
http://pediatrics.aappublications.org/current.shtml

Sexual Activity–Related Outcomes After Human Papillomavirus Vaccination of 11- to 12-Year-Olds
Robert A. Bednarczyk, Robert Davis, Kevin Ault, Walter Orenstein, and Saad B. Omer
Pediatrics 2012; 130:798-805

Abstract
OBJECTIVE: Previous surveys on hypothesized sexual activity changes after human papillomavirus (HPV) vaccination may be subject to self-response biases. To date, no studies measured clinical markers of sexual activity after HPV vaccination. This study evaluated sexual activity–related clinical outcomes after adolescent vaccination.

METHODS: We conducted a retrospective cohort study utilizing longitudinal electronic data from a large managed care organization. Girls enrolled in the managed care organization, aged 11 through 12 years between July 2006 and December 2007, were classified by adolescent vaccine (HPV; tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis, adsorbed; quadrivalent meningococcal conjugate) receipt. Outcomes (pregnancy/sexually transmitted infection testing or diagnosis; contraceptive counseling) were assessed through December 31, 2010, providing up to 3 years of follow-up. Incidence rate ratios comparing vaccination categories were estimated with multivariate Poisson regression, adjusting for health care–seeking behavior and demographic characteristics.

RESULTS: The cohort included 1398 girls (493 HPV vaccine–exposed; 905 HPV vaccine–unexposed). Risk of the composite outcome (any pregnancy/sexually transmitted infection testing or diagnosis or contraceptive counseling) was not significantly elevated in HPV vaccine–exposed girls relative to HPV vaccine–unexposed girls (adjusted incidence rate ratio: 1.29, 95% confidence interval [CI]: 0.92 to1.80; incidence rate difference: 1.6/100 person-years; 95% CI: −0.03 to 3.24). Incidence rate difference for Chlamydia infection (0.06/100 person-years [95% CI: −0.30 to 0.18]) and pregnancy diagnoses (0.07/100 person-years [95% CI: −0.20 to 0.35]), indicating little clinically meaningful absolute risk differences.

CONCLUSIONS: HPV vaccination in the recommended ages was not associated with increased sexual activity–related outcome rates.

Physician Attitudes Regarding School-Located Vaccinations

Pediatrics
November 2012, VOLUME 130 / ISSUE 5
http://pediatrics.aappublications.org/current.shtml

Physician Attitudes Regarding School-Located Vaccinations
Emily V. McCormick, Josh Durfee, Tara M. Vogt, Matthew F. Daley, Simon J. Hambidge, and Judith Shlay
Pediatrics 2012; 130:887-896

Abstract
OBJECTIVE: To assess physician attitudes regarding school-located adolescent vaccination and influenza vaccination.

METHODS: From July through September 2010, a 20-item survey was mailed to 1337 practicing Colorado family physicians and pediatricians. Standard statistical methods were used to examine unadjusted and adjusted odds ratios of factors associated with physician support for school-located vaccination programs.

RESULTS: Overall, 943 physicians were survey-eligible, and 584 (62%) responded. More than half of physicians supported both school-located influenza and adolescent vaccination. However, fewer physicians supported school-located adolescent vaccination compared with influenza vaccination. More physicians supported school-located vaccination for their publicly insured patients compared with their privately insured patients. Some family physicians (32%) and pediatricians (39%) believed that school-located vaccination would make their patients less likely to attend well-child visits, and half of respondents believed that school-located vaccination would have a negative financial impact on their practice. In multivariate analyses, physicians concerned about the financial impact of school-located vaccination were less likely to support such programs.

CONCLUSIONS: Although a majority of Colorado physicians supported influenza and adolescent vaccination at school, they expressed concerns regarding the implications on their practice. Lesser support for vaccination of their privately insured patients and concerns regarding attendance at well-child visits suggests the perceived financial impact from school-located vaccination is a barrier and merits additional examination.

A Quantitative and Novel Approach to the Prioritization of Zoonotic Diseases in North America: A Public Perspective

PLoS One
[Accessed 3 November 2012]
http://www.plosone.org/article/browse.action;jsessionid=577FD8B9E1F322DAA533C413369CD6F3.ambra01?field=date

A Quantitative and Novel Approach to the Prioritization of Zoonotic Diseases in North America: A Public Perspective
Victoria Ng, Jan M.
PLoS ONE: Research Article, published 01 Nov 2012 10.1371/journal.pone.0048519

Abstract
Background
Zoonoses account for over half of all communicable diseases causing illness in humans. As there are limited resources available for the control and prevention of zoonotic diseases, a framework for their prioritization is necessary to ensure resources are directed into those of highest importance. Although zoonotic outbreaks are a significant burden of disease in North America, the systematic prioritization of zoonoses in this region has not been previously evaluated.

Methodology/Principal Findings
This study describes the novel use of a well-established quantitative method, conjoint analysis (CA), to identify the relative importance of 21 key characteristics of zoonotic diseases that can be used for their prioritization in Canada and the US. Relative importance weights from the CA were used to develop a point-scoring system to derive a recommended list of zoonoses for prioritization in Canada and the US. Over 1,500 participants from the general public were recruited to complete the online survey (761 from Canada and 778 from the US). Hierarchical Bayes models were fitted to the survey data to derive CA-weighted scores. Scores were applied to 62 zoonotic diseases of public health importance in Canada and the US to rank diseases in order of priority.

Conclusions/Significance
This was the first study to describe a systematic and quantitative approach to the prioritization of zoonoses in North America involving public participants. We found individuals with no prior knowledge or experience in prioritizing zoonoses were capable of producing meaningful results using CA as a novel quantitative approach to prioritization. More similarities than differences were observed between countries suggesting general agreement in disease prioritization between Canadians and Americans. We demonstrate CA as a potential tool for the prioritization of zoonoses; other prioritization exercises may also consider this approach.

Parental Acceptance of HPV Vaccine in Peru: A Decision Framework

PLoS One
[Accessed 3 November 2012]
http://www.plosone.org/article/browse.action;jsessionid=577FD8B9E1F322DAA533C413369CD6F3.ambra01?field=date

Parental Acceptance of HPV Vaccine in Peru: A Decision Framework
Rosario M. Bartolini, Jennifer L. Winkler, Mary E. Penny, D. Scott LaMontagne
PLoS ONE: Research Article, published 29 Oct 2012 10.1371/journal.pone.0048017

Abstract 
Objective and Method
Cervical cancer is the third most common cancer affecting women worldwide and it is an important cause of death, especially in developing countries. Cervical cancer is caused by human papillomavirus (HPV) and can be prevented by HPV vaccine. The challenge is to expand vaccine availability to countries where it is most needed. In 2008 Peru’s Ministry of Health implemented a demonstration project involving 5th grade girls in primary schools in the Piura region. We designed and conducted a qualitative study of the decision-making process among parents of girls, and developed a conceptual model describing the process of HPV vaccine acceptance.

Results
We found a nonlinear HPV decision-making process that evolved over time. Initially, the vaccine’s newness, the requirement of written consent, and provision of information were important. If information was sufficient and provided by credible sources, many parents accepted the vaccine. Later, after obtaining additional information from teachers, health personnel, and other trusted sources, more parents accepted vaccination. An understanding of the issues surrounding the vaccine developed, parents overcome fears and rumors, and engaged in family negotiations–including hearing the girl’s voice in the decision-making process. The concept of prevention (cancer as danger, future health, and trust in vaccines) combined with pragmatic factors (no cost, available at school) and the credibility of the offer (information in the media, recommendation of respected authority figure) were central to motivations that led parents to decide to vaccinate their daughters. A lack of confidence in the health system was the primary inhibitor of vaccine acceptance.

Conclusions
Health personnel and teachers are credible sources of information and can provide important support to HPV vaccination campaigns.

Editorial: Bringing Clarity to the Reporting of Health Equity

PLoS Medicine
(Accessed 3 November 2012)
http://www.plosmedicine.org/article/browse.action?field=date

Bringing Clarity to the Reporting of Health Equity
The PLOS Medicine Editors Editorial, published 30 Oct 2012
doi:10.1371/journal.pmed.1001334

Health equity—the absence of avoidable and unfair differences in health, including access to health care—is relevant to virtually the whole of medicine and public health and encompasses much more than inequality alone. WHO [1] notes specifically that “health inequities involve more than inequality—whether in health determinants or outcomes, or in access to the resources needed to improve and maintain health—but [is also] also a failure to avoid or overcome such inequality that infringes human rights norms or is otherwise unfair.”

Inequity in health is widespread, is itself unevenly distributed globally within and between countries, and contributes to inequity in other areas of society more generally; two recent examples show that health inequity leads to disabled individuals in the UK having less access to cancer screening [2] and older people in Latin America, China, India, and Nigeria being excluded from access to health care because of health systems that finance medical services through out-of-pocket payments [3].

The WHO Commission on Social Determinants of Health (CSDH), which defined health equity as the absence of systematic differences in health, between and within countries, that are avoidable by reasonable action [4], makes it clear that understanding, documenting, and measuring inequity are crucial steps in determining this “reasonable action.” However, rigorous measurement and accurate evaluation of the effects of policies on health equity are not yet universal despite the CSDH calling for researchers to measure and understand the problem and assess the impact of action.

PLOS and PLOS Medicine have long had an interest in health equity. The first article PLOS Medicine ever published [5] discussed the 1994 International Conference on Population and Development (ICPD), in which unequal access to reproductive rights and its consequences were key concepts. PLOS Neglected Tropical Diseases’ first editorial, entitled “A New Voice for the Poor” [6], noted that “The neglected tropical diseases … represent some of humankind’s most ancient scourges and possibly our greatest global health disparities.” Over the years we have provided a forum for the discussion of many other aspects of health equity, including a paper published in November 2011 by Piroska Östlin and colleagues, which explicitly stated that   “Influencing regional and national research priorities on equity and health and their implementation requires joint efforts towards creating a critical mass of researchers, expanding collaborations and networks, and refining norms and standards” [7].

Another specific interest of PLOS Medicine, that of improving the reporting and conduct of research, now aligns with the goals of health equity and this call for refining of standards noted by Östlin and colleagues. We have been involved in the development and publication of revisions to the specific guidelines CONSORT (Consolidated Standards of Reporting Trials) [8] and PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) (previously QUOROM) guidelines [9] and overarching guidelines on developing reporting guidelines [10]; we have also supported the EQUATOR initiative on guidelines more generally [11]. We are therefore particularly pleased to be publishing this month the PRISMA-Equity 2012 extension [12], drafted during a meeting earlier this year (which included one author of this Editorial, VB), which provides reporting guidelines for systematic reviews with a specific focus on health equity. Most guidelines or extensions to reporting guidelines pertain to technical aspects, for example to improve the reporting of a specific study design such as cluster randomized trials, or for a specific intervention, such as acupuncture. Instead, the PRISMA-Equity 2012 extension is specifically aimed at improving the reporting of the relatively small proportion of systematic reviews in which health equity is a key focus.

At first sight, these guidelines may not fit into the usual technical reasons for the development of reporting guidelines. One issue discussed was whether moral reasons also drove a need for these guidelines. By developing this pragmatic tool, could they do more than just bring clarity to the reporting of specific papers; for example, could a reporting guideline even change outcomes? One paper cited by Welch and colleagues shows that vitamin A [13] has the largest absolute impact on mortality reduction for children with lowest nutritional status. Having that evidence presented as clearly as possible could potentially make the difference between an intervention being appropriately targeted, or not.

One of the original reporting guidelines, CONSORT, has done an enormous amount to raise awareness of the need for good reporting in this most experimental of human studies. Has it done more? The originators of CONSORT tend to shy away from this suggestion but guideline developers sometimes say that a good guideline is like a light shone into an untidy room; it does not tidy the room but shows where the mess is. Perhaps if the light were even turned on at the beginning of a study, there would be less “mess” throughout—and published results would also be clearer and more accurate. So, by shining a light on health equity research, as Welch and colleagues suggest, by providing “structured guidance on transparently reporting these methods and results,” the PRISMA-Equity 2012 guidelines have the potential to not only improve the state of the published literature, but also to “legitimize and emphasize the importance of reporting health equity results.” We are happy to support these dual aims and will endorse the use of these guidelines.

Author Contributions 

Wrote the first draft of the manuscript: VB. Contributed to the writing of the manuscript: VB EV JC PS MW LC. ICMJE criteria for authorship read and met: VB EV JC PS MW LC. Agree with manuscript results and conclusions: VB EV JC PS MW LC.

References

– World Health Organization (2012) Equity. Geneva: World Health Organization.

– Osborn DPJ, Horsfall L, Hassiotis A, Petersen I, Walters K, et al. (2012) Access to Cancer Screening in People with Learning Disabilities in the UK: Cohort Study in the Health Improvement Network, a Primary Care Research Database. PLoS ONE 7 (8) e43841 doi:10.1371/journal.pone.0043841. .

– Albanese E, Liu Z, Acosta D, Guerra M, Huang Y, et al. (2011) Equity in the Delivery of Community Healthcare to Older People: Findings from 10/66 Dementia Research Group Cross-sectional Surveys in Latin America, China, India and Nigeria. BMC Health Serv Res 11: 153 doi:10.1186/1472-6963-11-153. .

– World Health Organization (2008) Closing the Gap in a Generation: Health Equity through Action on the Social Determinants of Health. Commission on Social Determinants of Health Final Report. Geneva: World Health Organization. Available: http://www.who.int/social_determinants/t​hecommission/finalreport/en/index.html. Accessed: 26 September 2012.

– El Feki S (2004) The Birth of Reproductive Health: A Difficult Delivery. PLoS Med 1 (1) e9 doi:10.1371/journal.pmed.0010009. .

– Hotez P (2007) A New Voice for the Poor. PLoS Negl Trop Dis 1 (1) e77 doi:10.1371/journal.pntd.0000077. .

– Östlin P, Schrecker T, Sadana R, Bonnefoy J, Gilson L, et al. (2011) Priorities for Research on Equity and Health: Towards an Equity-Focused Health Research Agenda. PLoS Med 8 (11) e1001115 doi:10.1371/journal.pmed.1001115. .

– Schulz KF, Altman DG, Moher D (2010) for the CONSORT Group (2010) CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised Trials. PLoS Med 7 (3) e1000251 doi:10.1371/journal.pmed.1000251. .

– Moher D, Liberati A, Tetzlaff J, Altman DG (2009) The PRISMA Group (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6 (7) e1000097 doi:10.1371/journal.pmed.1000097. .

– Moher D, Schulz KF, Simera I, Altman DG (2010) Guidance for Developers of Health Research Reporting Guidelines. PLoS Med 7 (2) e1000217 doi:10.1371/journal.pmed.1000217. .

EQUATOR Network (2012) Home page. Available: http://www.equator-network.org/ Accessed 26 September 2012.

– Welch V, Petticrew M, Tugwell P, Moher D, O’Neill J, et al. (2012) PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity. PLoS Med 9 (10) e1001333 doi:10.1371/journal.pmed.1001333. .

– Imdad A, Herzer K, Mayo-Wilson E, Yakoob MY, Bhutta ZA (2010) Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age. Cochrane Database Syst Rev Issue 12. Art. No.: CD008524. doi:10.1002/14651858.CD008524.pub2. .

Policy Forum – Public Health: Optimizing Investments in Malaria Treatment and Diagnosis

Science        
2 November 2012 vol 338, issue 6107, pages 569-712
http://www.sciencemag.org/current.dtl

Policy Forum – Public Health
Optimizing Investments in Malaria Treatment and Diagnosis
Justin M. Cohen, Aaron M. Woolsey, Oliver J. Sabot, Peter W. Gething, Andrew J. Tatem, and Bruno Moonen
Science 2 November 2012: 612-614.

Better targeting of antimalarials to people who need them will maximize the impact of interventions in the private sector.

Summary
The Roll Back Malaria (RBM) Partnership has set an ambitious target of achieving near zero deaths from malaria by 2015 (1). Scale-up of insecticide-treated nets, indoor residual spraying of insecticide, and increased access to treatment with artemisinin-based combination therapies (ACTs) over the past decade have led to reductions in malaria incidence of more than 50% in 43 countries, including 8 in Africa (2). However, as an estimated 655,000 malaria deaths still occurred in 2010 (2), with the great majority in sub-Saharan Africa, substantial challenges remain.

Policy Forum – From Financing to Fevers: Lessons of an Antimalarial Subsidy Program

Science        
2 November 2012 vol 338, issue 6107, pages 569-712
http://www.sciencemag.org/current.dtl

Policy Forum – Public Health
From Financing to Fevers: Lessons of an Antimalarial Subsidy Program
Ramanan Laxminarayan, Kenneth Arrow, Dean Jamison, and Barry R. Bloom
Science 2 November 2012: 615-616.

Better approaches to affordable drugs, diagnostic tests, and patient-centered treatment are needed in Africa.

Summary
In 2001, the World Health Organization (WHO) recommended that countries use artemisinin-based combination therapies (ACTs) to treat malaria patients (1), as continued use of artemisinin monotherapies and substandard drugs had the potential to lead to widespread resistance to artemisinin, the most effective drug for malaria. But ACTs were unaffordable for most people in malaria-endemic countries, particularly in the private for-profit sector where most people seek treatment. Artemisinin monotherapies and the threat of resistance remain a problem. Resistance has now emerged in Cambodia and is spreading to Myanmar and Vietnam (2). Despite WHO’s efforts, monotherapies are produced by 37 pharmaceutical companies and marketed in 29 countries (3). Although resistance to artemisinin had not been detected at the time of the Institute of Medicine (IOM) report in 2004 (4), an IOM committee proposed a global subsidy high in the distribution chain, both to make ACTs inexpensive and to displace artemisinin monotherapy and other ineffective drugs.

Opinion – Europe Combating Poverty at Its Roots – David Cameron

Wall Street Journal
http://online.wsj.com/home-page
Accessed 3 November 2012

Opinion – Europe
Combating Poverty at Its Roots
Economic development requires aid, but also sound institutions. Britain can lead on both fronts.
By DAVID CAMERON

Excerpt
There is an old debate between those who say the way to tackle global poverty is to spend more on aid and those who believe instead that the solution is to deal with the weak institutions, corruption and conflict in developing countries. The truth is that right now, we need to do both.

We need to honor our promises to the poor, because people are dying unnecessarily and our aid is needed to save them. But we also need to tackle the causes of poverty, not just its symptoms. And that means a radical new approach to supporting what I call “the golden thread” of conditions that enable open economies and open societies to thrive: the rule of law, the absence of conflict and corruption, and the presence of property rights and strong institutions. It is only when people can get a job and a voice that they can take control of their own destiny and a build a future free from poverty.

I believe Britain is in a unique position to lead this new approach…

http://online.wsj.com/article/SB10001424052970204712904578090571423009066.html?KEYWORDS=cameron

From Google Scholar: Dissertations, Theses, Selected Journal Articles

From Google Scholar: Dissertations, Theses, Selected Journal Articles

Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells
KC Kwon, D Verma, ND Singh, R Herzog, H Daniell – Advanced Drug Delivery …, 2012
Abstract Among 12 billion injections administered annually, unsafe delivery leads to> 20
million infections and> 100 million reactions. In an emerging new concept, freeze-dried plant
cells (lettuce) expressing vaccine antigens/biopharmaceuticals are protected in the…

Inactivated poliovirus vaccine: The fog of uncertainty is lifting!
T Jacob John – Indian Pediatrics, 2012
India achieved zero transmission of wild polioviruses (WPVs) in 2011. On 25 February,
2012, the World Health Organization (WHO) removed India from the list of WPV-endemic
countries. Formal certification of eradication requires three years without WPVs, expected…

Did the FDA Fast Track Gardasil At the Risk of Adolescent Girls’ Health? That is the Question.
LCB Botha – J Law Med Ethics, 2012
There are not many public health issues where views are extremely polarized as those
concerning vaccines, and the HPV vaccine Gardasil is a case in point. … Too Fast or Not Too Fast: The FDA’s Approval of Merck’s HPV Vaccine Gardasil. J Law Med Ethics…